Limits...
Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.

Wilk A, Sajjan S, Modi A, Fan CP, Mavros P - Osteoporos Int (2014)

Bottom Line: Pharmacologic therapy is recommended to reduce future fracture risk.Pharmacologic therapy is recommended after osteoporotic fracture to reduce future fracture risk.Fracture liaison or adherence programs could lead to improved post-fracture treatment rates.

View Article: PubMed Central - PubMed

Affiliation: Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.

ABSTRACT

Unlabelled: Pharmacologic therapy is recommended to reduce future fracture risk. We examined osteoporosis medications dispensed to older women after first fracture. Only 23 % received therapy during the first year post-fracture. Prior osteoporosis therapy, a prior osteoporosis diagnosis, and older age were good predictors of post-fracture osteoporosis therapy.

Introduction: Pharmacologic therapy is recommended after osteoporotic fracture to reduce future fracture risk. The objective of this retrospective study was to examine osteoporosis therapy dispensed to women post-fracture.

Methods: We identified women ≥50 years old in a large administrative claims database from 2003 to mid-2012 who were continuously enrolled 2 years before (baseline) and 1 year after first osteoporotic fracture. Exclusions were Paget's disease or malignant neoplasm. Pre- and post-fracture osteoporosis therapies (oral and parenteral) were assessed overall and by fracture site.

Results: A total of 47,171 women of mean (SD) age of 63 (10) years were eligible; fractures included 8 % hip, 17 % vertebral, 73 % non-hip/non-vertebral, and 3 % multiple fracture sites. Only 18 % received osteoporosis therapy within 90 days and 23 % within 1 year post-fracture. Overall, 19 % of women had a prior osteoporosis diagnosis; 20 % had received osteoporosis therapy during baseline. Of 37,649 (80 %) women without baseline therapy, only 9 % initiated pharmacologic therapy within 1 year. The adjusted odds ratio (OR) of therapy within 1 year post-fracture was significantly greater for women who had received baseline osteoporosis therapy (versus none) and who had vertebral (OR 12.7, 95 % confidence interval (CI) 11.2-14.5), hip (15.2, 12.5-18.7), or non-hip/non-vertebral fracture (34.4, 31.7-37.3). Other significant predictors included pre-fracture osteoporosis diagnosis (1.6, 1.4-1.7) and older age (OR range, 1.3-1.7). Treatment adherence was significantly better among women with baseline osteoporosis diagnosis.

Conclusions: The substantial post-fracture treatment gap represents an important unmet need for women with osteoporotic fractures. Fracture liaison or adherence programs could lead to improved post-fracture treatment rates.

Show MeSH

Related in: MedlinePlus

Percentage of women prescribed with osteoporosis medication within 90 days and within 1 year post-fracture. Prior treatment was that dispensed during the baseline period; current treatment overlapped the index date. OP osteoporosis, Script prescription
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4221620&req=5

Fig1: Percentage of women prescribed with osteoporosis medication within 90 days and within 1 year post-fracture. Prior treatment was that dispensed during the baseline period; current treatment overlapped the index date. OP osteoporosis, Script prescription

Mentions: Figure 1 depicts the proportion of women who received osteoporosis therapy within 90 days and 1 year post-fracture, overall and according to prior (baseline period) osteoporosis therapy. A total of 8,445 (18 %) received medication within 90 days post-fracture; most of these women (6,656 [79 %]) had also received osteoporosis therapy during the baseline period. A total of 10,826 (23 %) women received medication within 1 year post-fracture, of which 68 % had received osteoporosis medication during baseline.Fig. 1


Post-fracture pharmacotherapy for women with osteoporotic fracture: analysis of a managed care population in the USA.

Wilk A, Sajjan S, Modi A, Fan CP, Mavros P - Osteoporos Int (2014)

Percentage of women prescribed with osteoporosis medication within 90 days and within 1 year post-fracture. Prior treatment was that dispensed during the baseline period; current treatment overlapped the index date. OP osteoporosis, Script prescription
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4221620&req=5

Fig1: Percentage of women prescribed with osteoporosis medication within 90 days and within 1 year post-fracture. Prior treatment was that dispensed during the baseline period; current treatment overlapped the index date. OP osteoporosis, Script prescription
Mentions: Figure 1 depicts the proportion of women who received osteoporosis therapy within 90 days and 1 year post-fracture, overall and according to prior (baseline period) osteoporosis therapy. A total of 8,445 (18 %) received medication within 90 days post-fracture; most of these women (6,656 [79 %]) had also received osteoporosis therapy during the baseline period. A total of 10,826 (23 %) women received medication within 1 year post-fracture, of which 68 % had received osteoporosis medication during baseline.Fig. 1

Bottom Line: Pharmacologic therapy is recommended to reduce future fracture risk.Pharmacologic therapy is recommended after osteoporotic fracture to reduce future fracture risk.Fracture liaison or adherence programs could lead to improved post-fracture treatment rates.

View Article: PubMed Central - PubMed

Affiliation: Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA.

ABSTRACT

Unlabelled: Pharmacologic therapy is recommended to reduce future fracture risk. We examined osteoporosis medications dispensed to older women after first fracture. Only 23 % received therapy during the first year post-fracture. Prior osteoporosis therapy, a prior osteoporosis diagnosis, and older age were good predictors of post-fracture osteoporosis therapy.

Introduction: Pharmacologic therapy is recommended after osteoporotic fracture to reduce future fracture risk. The objective of this retrospective study was to examine osteoporosis therapy dispensed to women post-fracture.

Methods: We identified women ≥50 years old in a large administrative claims database from 2003 to mid-2012 who were continuously enrolled 2 years before (baseline) and 1 year after first osteoporotic fracture. Exclusions were Paget's disease or malignant neoplasm. Pre- and post-fracture osteoporosis therapies (oral and parenteral) were assessed overall and by fracture site.

Results: A total of 47,171 women of mean (SD) age of 63 (10) years were eligible; fractures included 8 % hip, 17 % vertebral, 73 % non-hip/non-vertebral, and 3 % multiple fracture sites. Only 18 % received osteoporosis therapy within 90 days and 23 % within 1 year post-fracture. Overall, 19 % of women had a prior osteoporosis diagnosis; 20 % had received osteoporosis therapy during baseline. Of 37,649 (80 %) women without baseline therapy, only 9 % initiated pharmacologic therapy within 1 year. The adjusted odds ratio (OR) of therapy within 1 year post-fracture was significantly greater for women who had received baseline osteoporosis therapy (versus none) and who had vertebral (OR 12.7, 95 % confidence interval (CI) 11.2-14.5), hip (15.2, 12.5-18.7), or non-hip/non-vertebral fracture (34.4, 31.7-37.3). Other significant predictors included pre-fracture osteoporosis diagnosis (1.6, 1.4-1.7) and older age (OR range, 1.3-1.7). Treatment adherence was significantly better among women with baseline osteoporosis diagnosis.

Conclusions: The substantial post-fracture treatment gap represents an important unmet need for women with osteoporotic fractures. Fracture liaison or adherence programs could lead to improved post-fracture treatment rates.

Show MeSH
Related in: MedlinePlus